Similarly, compared with the US FDA-approved [177Lu]PSMA-617" to "[177Lu]Lu-PSMA-617, [177Lu]Lu-HTK03170 delivered 16.4-fold tumor absorbed dose, but only 1.7-fold absorbed dose to kidneys. The gene discussed is FOLH1; the disease is neoplasm.